5-methoxy-2,2-dimethyl-3,4-dihydro-2H-pyrrole | 107805-48-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 甲亚胺酸及其衍生物
• 英文名称: 5-methoxy-2,2-dimethyl-3,4-dihydro-2H-pyrrole
• 英文别名: 3,4-Dihydro-5-methoxy-2,2-dimethyl-2H-pyrrole；5-methoxy-2,2-dimethyl-3,4-dihydropyrrole
• CAS: 107805-48-1
• 化学式: C₇H₁₃NO
• 分子量: 127.186
• InChiKey: XBXVVUBUVBAYDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-氨基吡啶-2-羧酸 、 5-methoxy-2,2-dimethyl-3,4-dihydro-2H-pyrrole 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以40%的产率得到8,8-Dimethyl-7,8-dihydro-6H-pyrido[3,2-d]pyrrolo[1,2-a]pyrimidin-10-one
  参考文献：
  名称：

  Dunn; Kinnear; Norrie, Zeitschrift fur Chemie, 1986, vol. 26, # 8, p. 290 - 292

  摘要：

  DOI：
• 作为产物：
  描述：

  5,5-dimethyl-2-pyrrolidone 、 trimethoxonium tetrafluoroborate 以 二氯甲烷 为溶剂， 生成 5-methoxy-2,2-dimethyl-3,4-dihydro-2H-pyrrole
  参考文献：
  名称：

  [EN] APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE LA KINASE 1 RÉGULANT LE SIGNAL D'APOPTOSE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明揭示了式(I)的化合物，及其药学上可接受的盐和酯，其抑制与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾脏疾病、心血管疾病相关的细胞凋亡信号调节激酶1（ASK-1）。本发明还涉及包含上述化合物的药物组合物，用于给患有ASK-1相关疾病的受试者使用。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的ASK-1相关疾病的方法。本发明特别涉及治疗与肝脏脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）。

  公开号：

  WO2020198214A1

文献信息

• AMIDE DERIVATIVE INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF
  申请人：Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

  公开号：EP3590931A1

  公开（公告）日：2020-01-08

  An amide derivative inhibitor and a preparation method and an application thereof. Specifically relating to the compound shown in general formula (I), a preparation method for same, a pharmaceutical composition comprising said compound, and an application of same as an ASK inhibitor for the treatment of neurodegenerative disease, cardiovascular disease, inflammation, autoimmune and metabolic disease, each of the substituents in the general formula (I) being as defined in the description.

  一种酰胺衍生物抑制剂及其制备方法和应用。具体涉及到一般式(I)所示的化合物，其制备方法，包含该化合物的药物组合物，以及将其作为ASK抑制剂用于治疗神经退行性疾病、心血管疾病、炎症、自身免疫和代谢疾病的应用，一般式(I)中的每个取代基如描述中所定义。
• Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors
  申请人：Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

  公开号：US11136324B2

  公开（公告）日：2021-10-05

  An amide derivative inhibitor and a preparation method and an application thereof. Specifically relating to the compound shown in general formula (I), a preparation method for same, a pharmaceutical composition comprising said compound, and an application of same as an ASK inhibitor for the treatment of neurodegenerative disease, cardiovascular disease, inflammation, autoimmune and metabolic disease, each of the substituents in the general formula (I) being as defined in the description.

  一种酰胺衍生物抑制剂及其制备方法和应用。具体涉及通式（I）所示的化合物、其制备方法、包含所述化合物的药物组合物，以及其作为 ASK 抑制剂在治疗神经退行性疾病、心血管疾病、炎症、自身免疫和代谢疾病中的应用，通式（I）中的各取代基如描述中所定义。
• [EN] PHARMACEUTICAL COMPOSITION CONTAINING AMIDE DERIVATIVES, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF<br/>[FR] COMPOSITION PHARMACEUTIQUE CONTENANT DES DÉRIVÉS AMIDES, SON PROCÉDÉ DE PRÉPARATION ET APPLICATION ASSOCIÉE<br/>[ZH] 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
  申请人：JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD

  公开号：WO2020030107A1

  公开（公告）日：2020-02-13

  一种含有酰胺类衍生物的药物组合物及其制备方法和应用。特别的涉及一种药物组合物，包含通式(I)所示的化合物、其立体异构体或其药学上可接受的盐，药学上可接受的载体，及其作为ASK1抑制剂在治疗神经退休性疾病、心血管疾病、炎症、自身免疫和代谢性疾病的用途。
• APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20200308193A1

  公开（公告）日：2020-10-01

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).